Replies to post #112134 on Regen BioPharma Inc (RGBP)

[OTCShotCaller]

Thank you!

Your response to Q1/Q2 answered my question.

I was aware however of Gilead Sciences acquiring Kite for $11.9 B in 2017 if I remember the year correctly.

Thank you again for your reply and valuable input.

My only other question is do you perceive that Kite's mRNA Vaccine IP is based on the same NR2F6 Checkpoint inhibitor that RGBP's is based on, or is it a variation of it like Eli Lilly's. My understanding is that Eli Lilly & RGBP share common IP claim to NR2F6 but the molecule the !P is based on is not 100% identical. Is this the case with Kite's mRNA Cancer Vaccine IP? I have not been able to locate this specific information.

Your take on this would be much appreciated.

Best regards